Director/PDMR Shareholding

HALEON

22/05/2026 12:30

RNS Number : 4933F

Haleon PLC

22 May 2026

 

 

​Haleon plc: Director/PDMR Shareholding 

​ 

​22 May 2026: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").

 

On 21 May 2026, the Company was notified of the following transactions as detailed below.

 

1
Details of the issuer, emission allowance market participant
a)
Name
Haleon plc
b)
LEI
549300PSB3WWEODCUP19
2
Reason for the notification
a)
Position/status
Chief Financial Officer
b)
Initial notification /Amendment
Initial Notification
3
Details of the person discharging managerial responsibilities / person closely associated("PCA")
a)
PDMR/PCA
PDMR
b)
Name
Dawn Allen
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of Instrument
Identification code
Share
GB00BMX86B70
b)
Nature of the transaction
Acquisition of Ordinary Shares as a result of dividend reinvestment
c)
Currency, Price(s) and volume(s)
Price(s)
Volume(s)
£3.4022
2,596.07411
d)
Aggregated information
N/A
- Aggregated volume
- Price
e)
Date of the transaction
19 May 2026
f)
Place of the transaction
London Stock Exchange (XLON)

 

 

1
Details of the issuer, emission allowance market participant
a)
Name
Haleon plc
b)
LEI
549300PSB3WWEODCUP19
2
Reason for the notification
a)
Position/status
Chief Executive Officer
b)
Initial notification /Amendment
Initial Notification
3
Details of the person discharging managerial responsibilities / person closely associated("PCA")
a)
PDMR/PCA
PDMR
b)
Name
Brian McNamara
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of Instrument
Identification code
Share
GB00BMX86B70
b)
Nature of the transaction
Acquisition of Ordinary Shares as a result of dividend reinvestment
c)
Currency, Price(s) and volume(s)
Price(s)
Volume(s)
£3.4022
24,891.04716
d)
Aggregated information
N/A
- Aggregated volume
- Price
e)
Date of the transaction
19 May 2026
f)
Place of the transaction
London Stock Exchange (XLON)
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of Instrument
Identification code
Share
US4055521003
b)
Nature of the transaction
Acquisition of ADSsas a result of dividend reinvestment
c)
Currency, Price(s) and volume(s)
Price(s)
Volume(s)
$9.2446
4,414.93735
d)
Aggregated information
N/A
- Aggregated volume
- Price
e)
Date of the transaction
19 May 2026
f)
Place of the transaction
New York Stock Exchange (XNYS)


 

 

Amanda Mellor

Company Secretary

 

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.

 

For more information, please visit www.haleon.com. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHBGGDURUDDGLD